Seismic Pharmaceuticals

Seismic Therapeutic is a biotechnology company dedicated to discovering and developing next-generation biologics for the treatment of autoimmune diseases. The company utilizes its proprietary IMPACT platform, which integrates machine learning with structural biology, protein engineering, and translational immunology to accelerate drug discovery. Their lead candidate, S-1117, is a novel pan-IgG protease designed to treat chronic autoantibody-mediated diseases by rapidly lowering pathogenic IgG levels. Additionally, the company is developing S-4321, a PD-1 agonist aimed at restoring immune homeostasis. Seismic is backed by a strong syndicate of life science investors and led by experienced industry veterans in immunology and protein science.